The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The SARS‐CoV‐2 virus Omicron variant has now supplanted wild‐type virus as the dominant circulating strain globally. Three doses of mRNA COVID‐19 vaccine are recommended for transplant recipients as their primary vaccine series. However, the immunogenicity of mRNA vaccines as they specifically relate to the Omicron variant are not well studied. We analyzed Omicron‐specific neutralization in transplant...
Background
This pilot study assesses the ability of plasma collected from Canadian blood donors in the first wave of the SARS‐CoV‐2 pandemic to neutralize later SARS‐CoV‐2 variants of concern (VOCs).
Study design and methods
A repeated cross‐sectional design was used, and a random cross‐sectional sample of all available Canadian Blood Services retention samples (n = 1500/month) was drawn monthly...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.